METHODS AND PHARMACEUTICAL COMPOSITIONS COMPRISING A SGLT2 INHIBITOR FOR TREATING OR IMPROVING ERECTILE DYSFUNCTION
The invention relates to methods for improving glycemic control and for treating erectile dysfunction in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome wherein a SGLT2 inhibitor is administered to the patient. Furthermore the invention relates to a method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus or type 2 diabetes mellitus characterized in that in addition to the treatment of erectile dysfunction a SGLT2 inhibitor is administered to the patient. The invention also relates a pharmaceutical composition comprising a SGLT2 inhibitor and a compounds selected from the group consisting of PDE5 inhibitors or alprostadil.
1 . A method for improving glycemic control in a patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient, wherein the patient is a male patient diagnosed with erectile dysfunction.
2 . A method for treating erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient.
3 . The method according to claim 1 , wherein the patient is a poor-responder or a non-responder to a treatment with a PDE5 inhibitor.
4 . The method according to claim 1 , wherein the patient is over the age of 60 years.
5 . The method according to claim 1 , the patient has insufficient glycemic control despite antidiabetic treatment with one or more medicaments not including SGLT2 inhibitors.
6 . The method according to claim 1 , wherein in addition to the administration of a SGLT2 inhibitor one or more antidiabetic medicaments not belonging to the class of SGLT2 inhibitors are administered to the patient.
7 . The method according to claim 1 , wherein the SGLT2 inhibitor is empagliflozin.
8 . The method according to claim 7 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg.
9 . A method for improving a treatment of erectile dysfunction in a male patient diagnosed with prediabetes, type 1 diabetes mellitus, type 2 diabetes mellitus or metabolic syndrome comprising administering a SGLT2 inhibitor to the patient in addition to the treatment of erectile dysfunction.
10 . The method according to claim 9 , wherein characterized in that the treatment of erectile dysfunction comprises the administration of one or more medicaments selected from the group consisting of PDE5 inhibitors or alprostadil.
11 . The method according to claim 9 , wherein the SGLT2 inhibitor is empagliflozin.
12 . The method according to claim 11 , wherein empagliflozin is administered in an amount of 2.5 to 25 mg.
13 . A pharmaceutical composition comprising a SGLT2 inhibitor and one or more compounds selected from the group consisting of PDE5 inhibitors, apomorphin or alprostadil.
14 . The pharmaceutical composition according to claim 13 , wherein the SGLT2 inhibitor is empagliflozin.
15 . The pharmaceutical composition according to claim 13 , wherein the amount of empagliflozin is from 2.5 to 25 mg.